Track Collegium Pharmaceutical, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Collegium Pharmaceutical, Inc. COLL Open Collegium Pharmaceutical, Inc. in new tab

33.78 USD
P/E
17.38
EPS
2.06
P/B
3.71
ROE
27.41
Beta
0.76
Target Price
54.33 USD
Collegium Pharmaceutical, Inc. logo

Collegium Pharmaceutical, Inc.

🧾 Earnings Recap – Q1 2026

Collegium Pharmaceutical’s stock rose 3.5% after the quarter, driven by stronger-than-expected growth in JORNAY prescriptions and accelerated revenue from the ADHD portfolio, supported by the imminent AZSTARYS acquisition.

  • JORNAY prescriptions grew 14% year-over-year, generating $38.9 million in net revenue, up 36% year-over-year.
  • Pain portfolio net revenues increased 4% year-over-year to $154.6 million, underpinning steady cash flow.
  • Total net product revenues rose 9%, with adjusted EBITDA also up 9% year-over-year.
  • Generated $57.1 million in cash from operations, ending the quarter with a strong cash position of $421.8 million, up $35 million sequentially.
  • Proposed acquisition of AZSTARYS is progressing, expected to close in Q2, and anticipated to enhance growth, margin expansion, and portfolio longevity through 2037.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 6, 2026
P/E17.38
EPS2.06
Book Value9.64
Price to Book3.71
Debt/Equity297.58
% Insiders0.939%
Growth
Revenue Growth0.09%
Earnings Growth-0.47%
Estimates
Forward P/E5.03
Forward EPS7.11
Target Mean Price54.33

DCF Valuation

Tweak assumptions to recompute fair value for Collegium Pharmaceutical, Inc. (COLL)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Collegium Pharmaceutical, Inc. Logo Collegium Pharmaceutical, Inc. Analysis (COLL)

United States Health Care Official Website Stock

Is Collegium Pharmaceutical, Inc. a good investment? Collegium Pharmaceutical, Inc. (COLL) is currently trading at 33.78 USD. Market analysts have a consensus price target of 54.33 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 17.38. This valuation is generally in line with the broader market.

Earnings Schedule: Collegium Pharmaceutical, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is 7.11.

Investor FAQ

Does Collegium Pharmaceutical, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Collegium Pharmaceutical, Inc.?

Collegium Pharmaceutical, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of 2.06.

Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Exchange Ticker
NMS (United States) COLL
FRA (Germany) 354.F

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion